-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
November 19, 2021, drug trial center hosted fourBiological Pharmaceutical Co.
, Ltd.
Class 1 biological products Tetley monoclonal antibody injection in clinical application
.
, Ltd.
Tetlizumab Injection
(Source: CDE official website)
Tetley monoclonal antibody injection Tetley monoclonal antibody injection (codename: KL-A167) is a PD-L1 monoclonal antibody injection , is the second Corning Jerry 's Enwo Li monoclonal antibody injection , the cornerstone of Pharmaceutical After the sugarizumab injection , the third paragraph declares the domestically produced PD-L1 monoclonal antibody for the market
.
(Domestic PD-1/PD-L1 monoclonal antibodies that have been marketed/declared for listing: Sorting out: Target Society)
Today, the competition of PD-1 monoclonal antibody has become fierce.
Although the commercialization of domestic PD-L1 antibody is still close to the door, the degree of competition in the future is also predictable
.
In addition to the three PD-L1 monoclonal antibodies that are being declared, there are dozens of PD-L1 antibodies still in the development stage
.
(PD-L1 drugs under development.
Sorting out: Target Society)
Columbote
Columbote Kelun Pharmaceutical is a highly specialized and innovative pharmaceutical group.
Its subsidiaries include Sichuan Kelun Pharmaceutical Co.
, Ltd.
, Sichuan Kelun Botai Biomedical Co.
, Ltd.
, Sichuan Kelun Pharmaceutical Research Institute Co.
, Ltd.
, and Klus Pharma Inc.
USA Cologne), Cologne KAZ pharmaceutical Co.
, Ltd.
(Kazakhstan Cologne), Sichuan Kelun pharmaceutical Co.
, Ltd.
and so on more than 100 enterprises at home and abroad
.
It is reported that Kelun currently has 89 projects in the oncology field, including 54 targeted therapies, 20 immunotherapeutic drugs, 8 cytotoxic drugs and 7 tumor support therapies; 46 of which are innovative drugs, so far Eight innovative projects have been approved for INDs, including 1 NDA application submission, 1 phase III study, 1 critical phase II study, 1 phase II study, 3 phase I studies, and 1 IND pending approval
.
So far, Kelun has approved 6 anti-tumor drugs, namely Keyuxin® (gefitinib tablets), Keshulan® (zoledronic acid injection 100ml: 4mg), Keruifei®- Paclitaxel (albumin-bound type) for injection, Keshuxin® (sunitinib malate capsules), afatinib maleate tablets and Korrel® (erlotinib hydrochloride tablets)
.
(Product pipeline source: Klus Pharma Inc.
Reference source:
Reference source: Reference source:[1] CDE official website
[1] CDE official website[2] Kelun official website |Kelun official website |[3] KLUS Pharma | https:// KLUS Pharma | https://